Please ensure Javascript is enabled for purposes of website accessibility

Why Illumina Stock Is Skyrocketing Today

By Keith Speights - Updated Feb 12, 2021 at 12:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The genomic sequencing pioneer reported great fourth-quarter results.

What happened

Shares of Illumina (ILMN 0.08%) were skyrocketing 19% as of 11:30 a.m. EST on Friday. The big jump came after the genomic sequencing leader announced its fourth-quarter and full-year 2020 results following the market close on Thursday.

So what

Illumina reported record revenue in the fourth quarter of $953 million, up 20% from the third quarter and slightly higher than the prior-year period.

The company's adjusted earnings came in at $179 million, or $1.22 per diluted share. This was lower than Illumina's adjusted earnings of $252 million, or $1.70 per share, in the fourth quarter of 2019. But it easily beat the consensus Wall Street estimate of $1.11 per share.

Image of DNA over an outstretched hand

Image source: Getty Images.

It's smart not to put too much focus on any single quarter, whether good or bad. What's more important is the big picture: the growth prospects for the healthcare stock.

And the genomic sequencing pioneer's prospects are encouraging. CEO Francis deSouza said that the company expects a continued recovery from the pandemic, and that full-year revenue in 2021 will grow by 17% to 20%.

Now what

There are several things to watch with Illumina this year. The company expects to close its acquisition of the biotech GRAIL in the second half of 2021. Its partnerships with several drugmakers, including Bristol Myers Squibb and Merck, should begin to pay off.

Illumina should also achieve progress with its partnerships with Harvard Pilgrim Health Care targeting genetic disease testing, and with Sequoia Capital China to foster genomic start-ups in China.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Illumina, Inc. Stock Quote
Illumina, Inc.
ILMN
$233.74 (0.08%) $0.18
Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
MRK
$92.32 (2.11%) $1.91
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$76.91 (1.46%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.